Skip to content

Effect of transcranial direct current stimulation on older adults with mild cognitive impairment

Effect of transcranial direct current stimulation (tDCS) on cognitive function in older adults with mild cognitive impairment: a randomized, controlled study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/09/094250
Enrollment
40
Registered
2025-09-04
Start date
Unknown
Completion date
Unknown
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F06- Other mental disorders due to known physiological condition

Interventions

Intervention1: Active transcranial direct current stimulation: Group A will receive active tDCS (current intensity of 2 mA for 20 minutes with a ramp period of 10 seconds. A total of 10 sessions of a

Sponsors

nil
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1 Willingness to participate in the study 2 Age 55 years and above 3 Diagnosed with Mild Neurocognitive disorder as per DSM5 criteria

Exclusion criteria

Exclusion criteria: 1 Uncooperative patients or sensory deficits making assessment difficult 2 Refusal to give written informed consent for participation in the study and tDCS application 3 Medical comorbidities that need immediate attention or patients with terminal illness 4 Family or personal history of epilepsy 5 Any contraindication to tDCS such as History of Head injury or Implanted medical devices or Foreign body in head or eye 6 Scalp Injuries or Skin lesions 7 Presence of psychotic symptoms or suicidal ideations 8 Patients currently in Depression with HAMD score greater than 8 or in Delirium 9 Any other psychiatric comorbidity with exception to tobacco use disorder 10 Patients on procognitive drugs like donepezil or memantine etcectra 11 Current use of other neurostimulation treatments 12 Participants with abnormal thyroid function test or serum Vit B 12 level or Vit D3 level

Design outcomes

Primary

MeasureTime frame
Change in cognitive function assessed by ACE-HTimepoint: At End of 1st week, 2nd week, 3rd week

Secondary

MeasureTime frame
- ACE-H (total score) -Change in well-being WHO-Qol-Brief score -Side effect of tDCS Timepoint: At End of 1st week, 2nd week, 3rd week

Countries

India

Contacts

Public ContactShashank Saurabh Sinha

King george medical University

shashanksinha3@gmail.com8287188508

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026